Biogen reiterates late-stage M&A priority as it calls off planned aducanumab trial

As it contemplates exiting β-amyloid programs, Biogen is prioritizing late-stage M&A to shore up its pipeline and preparing to deliver near-term Phase II readouts from a stable of other non-Alzheimer's disease candidates. The bellwether also reported 1Q19 earnings Wednesday that came in ahead of the consensus.

EVP of R&D Michael Ehlers said on the company’s earnings call

Read the full 569 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE